MRNA - Moderna, Inc.
BioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines. Both have attractive pipelines that could lead to important new approvals over the next few years.
Moderna consolidates after a dramatic breakout, with a bullish pennant forming near resistance and offering a potential signal for another powerful advance.
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
Moderna receives a speculative Strong Buy rating after phase 3 melanoma data strengthens its oncology platform thesis. MRNA's upside hinges on Intismeran's ability to scale across multiple tumor types, not just melanoma. The 50/50 partnership with Merck provides both distribution strength and shared economics for Intismeran.
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
On Sept. 1, 2026, rising crude and Treasury yields pressured equities across nearly every sector, with tech stocks bearing the brunt of the selloff.
Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the stock is climbing anyway.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m.
Moderna and Merck recently announced positive results from a late-stage clinical study of their melanoma treatment. In recent years, Moderna has broadened its reach beyond its first product: the coronavirus vaccine.
Alyeska Investment Group L.P. cut its stake in shares of Moderna, Inc. (NASDAQ: MRNA) by 86.2% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 560,819 shares of the company's stock after selling 3,490,366 shares during the period. Alyeska Investment Group L.P. owned
Shares of Moderna, Inc. (NASDAQ: MRNA - Get Free Report) have received an average rating of "Hold" from the twenty-three research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and seven have issued a buy recommendation
Moderna has made an incredible comeback, surging sixfold over the past year and by around 127% over the past few weeks. The MRNA vaccine company recently announced promising news that could have major implications for its pivot toward oncology.
A woman with nearly $2 million saved sold her biotech shares when her boyfriend pressured her, watched the stock explode the next day, and then got dumped for it. Suze Orman had something to say about who actually came out ahead.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
A single trial readout is reshuffling the mRNA vaccine trade this morning. BioNTech SE (NASDAQ:BNTX | BNTX Price Prediction) stock is down 8% to $102.